Lantern Pharma (NASDAQ: LTRN), a leader in AI-driven oncology drug development, has announced the introduction of a new AI-powered module within its RADR(R) platform. This innovative tool is designed to predict the effectiveness of combination therapies that involve DNA-damaging agents (DDAs) and DNA damage response inhibitors (DDRis), based on a comprehensive analysis of 221 clinical trials. The module aims to facilitate the precise, biomarker-guided design of cancer treatment regimens, potentially reducing development time and cost by up to one-third.
The technology has already played a pivotal role in designing Lantern’s FDA-cleared Phase 1B/2 trial for triple-negative breast cancer, which combines LP-184 and olaparib. With the potential to revolutionize the approach to cancer treatment, Lantern Pharma is actively seeking licensing and commercialization opportunities to extend the application of this system across various oncology indications. This development represents a significant step forward in the fight against cancer, offering hope for more effective and efficient treatment options.
For further details, visit https://ibn.fm/NVQqv.
